U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H25FO5S
Molecular Weight 444.5177
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CANAGLIFLOZIN ANHYDROUS

SMILES

Cc1ccc(cc1Cc2ccc(-c3ccc(cc3)F)s2)[C@@]4([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(CO)O4)O)O)O

InChI

InChIKey=XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H25FO5S
Molecular Weight 444.5177
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Canagliflozin (INN, trade name Invokana or Sulisent) is a drug of the gliflozin class. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an antidiabetic drug used to improve glycemic control in people with type 2 diabetes. Sodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion. In extensive clinical trials, canagliflozin produced a consistent dose-dependent reduction in HbA1c of 0.77% to 1.16% when administered as monotherapy, combination with metformin, combination with metformin and a sulfonylurea, combination with metformin and pioglitazone, and in combination with insulin from a baselines of 7.8% to 8.1%, in combination with metformin, or in combination with metformin and a sulfonylurea. When added to metformin, canagliflozin 100 mg was shown to be non-inferior to both sitagliptin 100 mg and glimepiride in reductions on HbA1c at one year, whilst canagliflozin 300 mg successfully demonstrated statistical superiority over both sitagliptin and glimiperide in HbA1c reductions. Secondary efficacy endpoint of superior body weight reduction and blood pressure reduction (versus sitagliptin and glimiperide)) were observed as well. Canagliflozin produces beneficial effects on HDL cholesterol whilst increasing LDL cholesterol to produce no change in total cholesterol.

Originator

Curator's Comment:: Invokana (canagliflozin) was first developed by Mitsubishi Tanabe Pharma Corporation in Japan and later licensed to Janssen Pharmaceuticals.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P31639
Gene ID: 6524.0
Gene Symbol: SLC5A2
Target Organism: Homo sapiens (Human)
4.4 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
INVOKANA

Approved Use

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis

Launch Date

1.36451523E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1178 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANAGLIFLOZIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10521 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANAGLIFLOZIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANAGLIFLOZIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 833
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 833
Sources: Page: 129
Disc. AE: Nausea, Pneumonia...
AEs leading to
discontinuation/dose reduction:
Nausea (0.2%)
Pneumonia (0.4%)
Vulvovaginal mycotic infection (0.4%)
Glomerular filtration rate decreased (0.2%)
Weight decreased (0.2%)
Pollakiuria (0.1%)
Epidermal and dermal conditions (0.6%)
Sources: Page: 129
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 834
Sources: Page: 129
Disc. AE: Blood creatinine increased, Blood potassium increased...
AEs leading to
discontinuation/dose reduction:
Blood creatinine increased (0.2%)
Blood potassium increased (0.2%)
Glomerular filtration rate decreased (0.6%)
Weight decreased (0.1%)
Pollakiuria (0.2%)
Sources: Page: 129
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 425
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: F
Population Size: 425
Sources: Page: 9
Other AEs: Genital infection female, Vulvovaginal pruritus...
Other AEs:
Genital infection female (10.6%)
Vulvovaginal pruritus (1.6%)
Sources: Page: 9
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 430
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M
Population Size: 430
Sources: Page: 9
Other AEs: Genital infection male...
Other AEs:
Genital infection male (4.2%)
Sources: Page: 9
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Other AEs: Urinary tract infections, Urination abnormal NOS...
Other AEs:
Urinary tract infections (5.9%)
Urination abnormal NOS (5.1%)
Thirst (2.8%)
Constipation (1.8%)
Nausea (2.1%)
Sources: Page: 9
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 425
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: F
Population Size: 425
Sources: Page: 9
Other AEs: Genital infection female, Vulvovaginal pruritus...
Other AEs:
Genital infection female (11.6%)
Vulvovaginal pruritus (3.2%)
Sources: Page: 9
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 842
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: F
Population Size: 842
Sources: Page: 9
Disc. AE: Mycoplasma genitalium infection...
AEs leading to
discontinuation/dose reduction:
Mycoplasma genitalium infection (0.7%)
Sources: Page: 9
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 430
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M
Population Size: 430
Sources: Page: 9
Other AEs: Genital infection male...
Other AEs:
Genital infection male (3.8%)
Sources: Page: 9
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 825
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M
Population Size: 825
Sources: Page: 9
Disc. AE: Mycoplasma genitalium infection...
AEs leading to
discontinuation/dose reduction:
Mycoplasma genitalium infection (0.5%)
Sources: Page: 9
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 1667
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 1667
Sources: Page: 9
Disc. AE: Hypersensitivity...
Other AEs: Limb amputation...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity (2 patients)
Other AEs:
Limb amputation
Sources: Page: 9
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Other AEs: Urinary tract infections, Urination abnormal NOS...
Other AEs:
Urinary tract infections (4.4%)
Urination abnormal NOS (4.6%)
Thirst (2.4%)
Constipation (2.4%)
Nausea (2.3%)
Sources: Page: 9
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 56
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 56
Sources:
Other AEs: Pollakiuria...
Other AEs:
Pollakiuria (below serious, 3 patients)
Sources:
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Other AEs: Anaemia vitamin B12 deficiency, Disseminated intravascular coagulation...
Other AEs:
Anaemia vitamin B12 deficiency (serious, 1 patient)
Disseminated intravascular coagulation (serious, 1 patient)
Anaemia hypochromic (serious, 1 patient)
Anaemia iron deficiency (serious, 2 patients)
Lymphadenopathy (serious, 1 patient)
Pancytopenia (serious, 1 patient)
Acute coronary syndrome (serious, 12 patients)
Angina pectoris (serious, 21 patient)
Arrhythmia (serious, 2 patients)
Arteriosclerosis coronary artery (serious, 4 patients)
Atrioventricular block first degree (serious, 1 patient)
Cardiac tamponade (serious, 1 patient)
Cardio-respiratory arrest (serious, 4 patients)
Cor pulmonale (serious, 1 patient)
Coronary artery occlusion (serious, 3 patients)
Hypertensive heart disease (serious, 2 patients)
Myocarditis (serious, 1 patient)
Right ventricular failure (serious, 1 patient)
Ventricular extrasystoles (serious, 2 patients)
Vertigo positional (serious, 1 patient)
Goitre (serious, 2 patients)
Hypothyroidism (serious, 1 patient)
Inappropriate antidiuretic hormone secretion (serious, 1 patient)
Thyroid mass (serious, 2 patients)
Diabetic retinopathy (serious, 7 patients)
Maculopathy (serious, 2 patients)
Ischaemic optic neuropathy (serious, 1 patient)
Retinal detachment (serious, 3 patients)
Uveitis (serious, 1 patient)
Vitreous adhesions (serious, 1 patient)
Vitreous haemorrhage (serious, 4 patients)
Abdominal fat apron (serious, 1 patient)
Abdominal incarcerated hernia (serious, 1 patient)
Abdominal pain lower (serious, 1 patient)
Anal haemorrhage (serious, 1 patient)
Colitis (serious, 1 patient)
Diarrhoea (serious, 3 patients)
Diverticulum (serious, 1 patient)
Diverticulum intestinal haemorrhagic (serious, 1 patient)
Duodenal ulcer (serious, 2 patients)
Duodenitis (serious, 2 patients)
Faeces discoloured (serious, 1 patient)
Food poisoning (serious, 1 patient)
Gastric ulcer (serious, 2 patients)
Gastritis (serious, 3 patients)
Hernia inguinal (serious, 4 patients)
Intestinal obstruction (serious, 7 patients)
Intestinal perforation (serious, 1 patient)
Leukoplakia oral (serious, 1 patient)
Lower gastrointestinal haemorrhage (serious, 1 patient)
Melaena (serious, 1 patient)
Obstructive pancreatitis (serious, 1 patient)
Pancreatitis (serious, 4 patients)
Rectal polyp (serious, 1 patient)
Small intestinal haemorrhage (serious, 1 patient)
Umbilical hernia (serious, 1 patient)
Upper gastrointestinal haemorrhage (serious, 4 patients)
Cardiac death (serious, 3 patients)
Complication associated with device (serious, 1 patient)
Critical illness (serious, 1 patient)
Death (serious, 7 patients)
Gait disturbance (serious, 1 patient)
General physical health deterioration (serious, 1 patient)
Hernia incarcerated (serious, 1 patient)
Non-cardiac chest pain (serious, 8 patients)
Pyrexia (serious, 2 patients)
Systemic inflammatory response syndrome (serious, 1 patient)
Cholangitis acute (serious, 1 patient)
Cholangitis sclerosing (serious, 1 patient)
Cholecystitis acute (serious, 5 patients)
Cholecystitis chronic (serious, 3 patients)
Cholelithiasis (serious, 5 patients)
Hepatic function abnormal (serious, 1 patient)
Abdominal sepsis (serious, 1 patient)
Abscess limb (serious, 3 patients)
Acute hepatitis B (serious, 1 patient)
Arthritis bacterial (serious, 2 patients)
Atypical pneumonia (serious, 1 patient)
Campylobacter colitis (serious, 1 patient)
Clostridium difficile colitis (serious, 2 patients)
Clostridium difficile infection (serious, 1 patient)
Cystitis (serious, 2 patients)
Device related infection (serious, 1 patient)
Diabetic gangrene (serious, 5 patients)
Diverticulitis (serious, 4 patients)
Ear infection (serious, 1 patient)
Empyema (serious, 1 patient)
Enterobacter infection (serious, 1 patient)
Gas gangrene (serious, 1 patient)
Gastroenteritis bacterial (serious, 1 patient)
Graft infection (serious, 1 patient)
Haemophilus infection (serious, 1 patient)
Influenza (serious, 3 patients)
Laryngitis (serious, 1 patient)
Fasciitis necrotising (serious, 2 patients)
Onychomycosis (serious, 1 patient)
Osteomyelitis acute (serious, 2 patients)
Chronic osteomyelitis (serious, 1 patient)
Perineal abscess (serious, 1 patient)
Pharyngeal abscess (serious, 1 patient)
Pneumococcal pneumonia (serious, 1 patient)
Pneumonia streptococcal (serious, 1 patient)
Pulmonary sepsis (serious, 1 patient)
Pyelonephritis acute (serious, 4 patients)
Rectal abscess (serious, 1 patient)
Respiratory tract infection viral (serious, 1 patient)
Scrub typhus (serious, 1 patient)
Soft tissue infection (serious, 1 patient)
Infection staphylococcal (serious, 1 patient)
Subcutaneous abscess (serious, 1 patient)
Tonsillitis (serious, 1 patient)
Urinary tract infection (serious, 25 patients)
Urinary tract infection fungal (serious, 1 patient)
Wound infection (serious, 6 patients)
Concussion (serious, 1 patient)
Facial bones fracture (serious, 1 patient)
Femoral neck fracture (serious, 4 patients)
Femur fracture (serious, 5 patients)
Fibula fracture (serious, 2 patients)
Foot fracture (serious, 1 patient)
Fracture displacement (serious, 1 patient)
Humerus fracture (serious, 4 patients)
Joint dislocation (serious, 1 patient)
Ligament rupture (serious, 1 patient)
Limb injury (serious, 1 patient)
Meniscus injury (serious, 1 patient)
Muscle strain (serious, 1 patient)
Post procedural haemorrhage (serious, 1 patient)
Postoperative thrombosis (serious, 1 patient)
Postoperative wound complication (serious, 1 patient)
Pubis fracture (serious, 2 patients)
Road traffic accident (serious, 1 patient)
Soft tissue injury (serious, 1 patient)
Sternal fracture (serious, 1 patient)
Stress fracture (serious, 1 patient)
Haemorrhage subdural (serious, 1 patient)
Thermal burn (serious, 2 patients)
Thoracic vertebral fracture (serious, 1 patient)
Tibia fracture (serious, 2 patients)
Ulna fracture (serious, 2 patients)
Vascular graft occlusion (serious, 2 patients)
Aspiration bronchial (serious, 1 patient)
Biopsy kidney (serious, 1 patient)
Blood creatine phosphokinase increased (serious, 2 patients)
Blood urea increased (serious, 1 patient)
Glomerular filtration rate decreased (serious, 5 patients)
Cachexia (serious, 1 patient)
Diabetic ketoacidosis (serious, 9 patients)
Fluid retention (serious, 1 patient)
Hypoglycaemia (serious, 17 patients)
Hypophagia (serious, 1 patient)
Lactic acidosis (serious, 1 patient)
Obesity (serious, 2 patients)
Back pain (serious, 2 patients)
Cervical spinal stenosis (serious, 1 patient)
Haemarthrosis (serious, 1 patient)
Intervertebral disc degeneration (serious, 1 patient)
Muscular weakness (serious, 2 patients)
Musculoskeletal chest pain (serious, 2 patients)
Osteitis (serious, 1 patient)
Osteochondrosis (serious, 1 patient)
Spinal column stenosis (serious, 1 patient)
Osteoarthritis spinal (serious, 4 patients)
Symphysiolysis (serious, 1 patient)
Acute leukaemia (serious, 1 patient)
Adenocarcinoma of colon (serious, 2 patients)
B-cell lymphoma (serious, 1 patient)
Basal cell carcinoma (serious, 2 patients)
Bladder cancer (serious, 5 patients)
Brain cancer metastatic (serious, 1 patient)
Brain neoplasm (serious, 1 patient)
Breast cancer (serious, 3 patients)
Cholangiocarcinoma (serious, 2 patients)
Colon adenoma (serious, 1 patient)
Colon cancer (serious, 6 patients)
Endometrial adenocarcinoma (serious, 1 patient)
Gastric cancer (serious, 3 patients)
Gastric neoplasm (serious, 1 patient)
Hepatic neoplasm (serious, 1 patient)
Invasive breast carcinoma (serious, 1 patient)
Invasive ductal breast carcinoma (serious, 2 patients)
Invasive lobular breast carcinoma (serious, 1 patient)
Large intestine benign neoplasm (serious, 1 patient)
Laryngeal cancer (serious, 1 patient)
Lung cancer metastatic (serious, 2 patients)
Lung neoplasm (serious, 2 patients)
Malignant meningioma (serious, 1 patient)
Metastases to bone (serious, 2 patients)
Metastatic renal cell carcinoma (serious, 1 patient)
Myelodysplastic syndrome (serious, 1 patient)
Oesophageal adenocarcinoma (serious, 1 patient)
Ovarian endometrioid carcinoma (serious, 1 patient)
Pancreatic carcinoma metastatic (serious, 1 patient)
Pancreatic neoplasm (serious, 1 patient)
Prostate cancer (serious, 8 patients)
Prostatic adenoma (serious, 2 patients)
Rectal adenoma (serious, 1 patient)
Renal oncocytoma (serious, 1 patient)
Salivary gland neoplasm (serious, 1 patient)
Squamous cell carcinoma of skin (serious, 2 patients)
Transitional cell cancer of the renal pelvis and ureter (serious, 2 patients)
Transitional cell carcinoma (serious, 3 patients)
Brain injury (serious, 1 patient)
Brain oedema (serious, 2 patients)
Carpal tunnel syndrome (serious, 2 patients)
Cauda equina syndrome (serious, 1 patient)
Cerebellar haemorrhage (serious, 1 patient)
Cerebellar stroke (serious, 1 patient)
Chronic inflammatory demyelinating polyradiculoneuropathy (serious, 1 patient)
Clonus (serious, 1 patient)
Dementia (serious, 2 patients)
Diabetic autonomic neuropathy (serious, 1 patient)
Diabetic hyperosmolar coma (serious, 1 patient)
Embolic cerebral infarction (serious, 1 patient)
Encephalopathy (serious, 2 patients)
Facial paralysis (serious, 1 patient)
Generalised tonic-clonic seizure (serious, 1 patient)
Haemorrhagic transformation stroke (serious, 1 patient)
Intracranial mass (serious, 1 patient)
Ischaemic neuropathy (serious, 1 patient)
Lumbosacral radiculopathy (serious, 1 patient)
Metabolic encephalopathy (serious, 1 patient)
Myelopathy (serious, 1 patient)
Paraparesis (serious, 1 patient)
Parkinson's disease (serious, 1 patient)
Peripheral sensorimotor neuropathy (serious, 1 patient)
Polyneuropathy (serious, 1 patient)
Seizure (serious, 2 patients)
Spinal cord compression (serious, 1 patient)
Syncope (serious, 4 patients)
Tension headache (serious, 2 patients)
Transient ischaemic attack (serious, 10 patients)
Vasculitis cerebral (serious, 1 patient)
VIth nerve paralysis (serious, 1 patient)
Abortion spontaneous (serious, 1 patient)
Retained products of conception (serious, 1 patient)
Confusional state (serious, 2 patients)
Substance-induced psychotic disorder (serious, 1 patient)
Suicide attempt (serious, 1 patient)
Anuria (serious, 1 patient)
Bladder cyst (serious, 1 patient)
Calculus urinary (serious, 1 patient)
Diabetic nephropathy (serious, 12 patients)
Nephrolithiasis (serious, 1 patient)
Nephrotic syndrome (serious, 2 patients)
Bladder neurogenic (serious, 1 patient)
Colic renal (serious, 1 patient)
Renal impairment (serious, 10 patients)
Renal injury (serious, 1 patient)
Renal tubular necrosis (serious, 1 patient)
Stress urinary incontinence (serious, 1 patient)
Ureterolithiasis (serious, 1 patient)
Urinary retention (serious, 2 patients)
Adenomyosis (serious, 1 patient)
Cervix disorder (serious, 1 patient)
Cystocele (serious, 1 patient)
Ovarian cyst (serious, 1 patient)
Rectocele (serious, 1 patient)
Uterine prolapse (serious, 1 patient)
Uterovaginal prolapse (serious, 1 patient)
Prolapse vaginal (serious, 1 patient)
Asthma (serious, 2 patients)
Bronchiectasis (serious, 1 patient)
Bronchitis chronic (serious, 1 patient)
Bronchospasm (serious, 1 patient)
Chronic respiratory failure (serious, 1 patient)
Cough (serious, 2 patients)
Dyspnoea at rest (serious, 1 patient)
Hypoxia (serious, 1 patient)
Laryngeal haematoma (serious, 1 patient)
Pleuritic pain (serious, 1 patient)
Pulmonary embolism (serious, 7 patients)
Pulmonary fibrosis (serious, 4 patients)
Pulmonary infarction (serious, 1 patient)
Angioedema (serious, 2 patients)
Diabetic foot (serious, 15 patients)
Diabetic ulcer (serious, 1 patient)
Drug eruption (serious, 1 patient)
Erythema (serious, 1 patient)
Neuropathic ulcer (serious, 1 patient)
Generalised rash (serious, 1 patient)
Skin ulcer (serious, 18 patients)
Accelerated hypertension (serious, 1 patient)
Aortic dissection (serious, 1 patient)
Arterial disorder (serious, 1 patient)
Arterial insufficiency (serious, 1 patient)
Circulatory collapse (serious, 1 patient)
Extremity necrosis (serious, 9 patients)
Haematoma (serious, 2 patients)
Hypotension (serious, 4 patients)
Claudication intermittent (serious, 1 patient)
Leriche syndrome (serious, 1 patient)
Peripheral artery occlusion (serious, 2 patients)
Disorder peripheral vascular (serious, 5 patients)
Peripheral venous disease (serious, 1 patient)
Haemorrhagic shock (serious, 1 patient)
Subclavian artery stenosis (serious, 1 patient)
Thrombosis (serious, 1 patient)
Vascular occlusion (serious, 1 patient)
Diabetic retinopathy (below serious, 65 patients)
Nausea (below serious, 54 patients)
Onychomycosis (below serious, 45 patients)
Urinary tract infection (below serious, 202 patients)
Pain in extremity (below serious, 56 patients)
Headache (below serious, 69 patients)
Skin ulcer (below serious, 85 patients)
Hypotension (below serious, 57 patients)
Sources:
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 13
Sources:
Other AEs: Pneumonia...
Other AEs:
Pneumonia (serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Pollakiuria 0.1%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 833
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 833
Sources: Page: 129
Glomerular filtration rate decreased 0.2%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 833
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 833
Sources: Page: 129
Nausea 0.2%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 833
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 833
Sources: Page: 129
Weight decreased 0.2%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 833
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 833
Sources: Page: 129
Pneumonia 0.4%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 833
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 833
Sources: Page: 129
Vulvovaginal mycotic infection 0.4%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 833
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 833
Sources: Page: 129
Epidermal and dermal conditions 0.6%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 833
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 833
Sources: Page: 129
Weight decreased 0.1%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 834
Sources: Page: 129
Blood creatinine increased 0.2%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 834
Sources: Page: 129
Blood potassium increased 0.2%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 834
Sources: Page: 129
Pollakiuria 0.2%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 834
Sources: Page: 129
Glomerular filtration rate decreased 0.6%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 129
unhealthy, adult
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 834
Sources: Page: 129
Vulvovaginal pruritus 1.6%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 425
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: F
Population Size: 425
Sources: Page: 9
Genital infection female 10.6%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 425
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: F
Population Size: 425
Sources: Page: 9
Genital infection male 4.2%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 430
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M
Population Size: 430
Sources: Page: 9
Constipation 1.8%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Nausea 2.1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Thirst 2.8%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Urination abnormal NOS 5.1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Urinary tract infections 5.9%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Genital infection female 11.6%
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 425
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: F
Population Size: 425
Sources: Page: 9
Vulvovaginal pruritus 3.2%
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 425
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: F
Population Size: 425
Sources: Page: 9
Mycoplasma genitalium infection 0.7%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 842
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: F
Population Size: 842
Sources: Page: 9
Genital infection male 3.8%
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 430
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M
Population Size: 430
Sources: Page: 9
Mycoplasma genitalium infection 0.5%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 825
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M
Population Size: 825
Sources: Page: 9
Limb amputation
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 1667
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 1667
Sources: Page: 9
Hypersensitivity 2 patients
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 1667
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 1667
Sources: Page: 9
Nausea 2.3%
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Constipation 2.4%
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Thirst 2.4%
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Urinary tract infections 4.4%
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Urination abnormal NOS 4.6%
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources: Page: 9
unhealthy, mean 56 years
n = 834
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: mean 56 years
Sex: M+F
Population Size: 834
Sources: Page: 9
Pollakiuria below serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 56
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 56
Sources:
Urinary tract infection below serious, 202 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Onychomycosis below serious, 45 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Nausea below serious, 54 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pain in extremity below serious, 56 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hypotension below serious, 57 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diabetic retinopathy below serious, 65 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Headache below serious, 69 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Skin ulcer below serious, 85 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Abdominal fat apron serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Abdominal incarcerated hernia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Abdominal pain lower serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Abdominal sepsis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Abortion spontaneous serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Accelerated hypertension serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Acute hepatitis B serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Acute leukaemia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Adenomyosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Anaemia hypochromic serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Anaemia vitamin B12 deficiency serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Anal haemorrhage serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Anuria serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Aortic dissection serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Arterial disorder serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Arterial insufficiency serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Aspiration bronchial serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Atrioventricular block first degree serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Atypical pneumonia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
B-cell lymphoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Biopsy kidney serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Bladder cyst serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Bladder neurogenic serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Blood urea increased serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Brain cancer metastatic serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Brain injury serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Brain neoplasm serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Bronchiectasis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Bronchitis chronic serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Bronchospasm serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cachexia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Calculus urinary serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Campylobacter colitis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cardiac tamponade serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cauda equina syndrome serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cerebellar haemorrhage serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cerebellar stroke serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cervical spinal stenosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cervix disorder serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cholangitis acute serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cholangitis sclerosing serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Chronic inflammatory demyelinating polyradiculoneuropathy serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Chronic osteomyelitis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Chronic respiratory failure serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Circulatory collapse serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Claudication intermittent serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Clonus serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Clostridium difficile infection serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Colic renal serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Colitis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Colon adenoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Complication associated with device serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Concussion serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cor pulmonale serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Critical illness serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cystocele serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Device related infection serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diabetic autonomic neuropathy serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diabetic hyperosmolar coma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diabetic ulcer serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Disseminated intravascular coagulation serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diverticulum intestinal haemorrhagic serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diverticulum serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Drug eruption serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Dyspnoea at rest serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Ear infection serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Embolic cerebral infarction serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Empyema serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Endometrial adenocarcinoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Enterobacter infection serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Erythema serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Facial bones fracture serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Facial paralysis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Faeces discoloured serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Fluid retention serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Food poisoning serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Foot fracture serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Fracture displacement serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Gait disturbance serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Gas gangrene serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Gastric neoplasm serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Gastroenteritis bacterial serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
General physical health deterioration serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Generalised rash serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Generalised tonic-clonic seizure serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Graft infection serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Haemarthrosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Haemophilus infection serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Haemorrhage subdural serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Haemorrhagic shock serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Haemorrhagic transformation stroke serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hepatic function abnormal serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hepatic neoplasm serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hernia incarcerated serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hypophagia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hypothyroidism serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hypoxia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Inappropriate antidiuretic hormone secretion serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Infection staphylococcal serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Intervertebral disc degeneration serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Intestinal perforation serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Intracranial mass serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Invasive breast carcinoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Invasive lobular breast carcinoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Ischaemic neuropathy serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Ischaemic optic neuropathy serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Joint dislocation serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Lactic acidosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Large intestine benign neoplasm serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Laryngeal cancer serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Laryngeal haematoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Laryngitis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Leriche syndrome serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Leukoplakia oral serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Ligament rupture serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Limb injury serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Lower gastrointestinal haemorrhage serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Lumbosacral radiculopathy serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Lymphadenopathy serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Malignant meningioma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Melaena serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Meniscus injury serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Metabolic encephalopathy serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Metastatic renal cell carcinoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Muscle strain serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Myelodysplastic syndrome serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Myelopathy serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Myocarditis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Nephrolithiasis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Neuropathic ulcer serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Obstructive pancreatitis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Oesophageal adenocarcinoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Onychomycosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Osteitis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Osteochondrosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Ovarian cyst serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Ovarian endometrioid carcinoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pancreatic carcinoma metastatic serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pancreatic neoplasm serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pancytopenia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Paraparesis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Parkinson's disease serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Perineal abscess serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Peripheral sensorimotor neuropathy serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Peripheral venous disease serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pharyngeal abscess serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pleuritic pain serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pneumococcal pneumonia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pneumonia streptococcal serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Polyneuropathy serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Post procedural haemorrhage serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Postoperative thrombosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Postoperative wound complication serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Prolapse vaginal serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pulmonary infarction serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pulmonary sepsis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Rectal abscess serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Rectal adenoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Rectal polyp serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Rectocele serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Renal injury serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Renal oncocytoma serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Renal tubular necrosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Respiratory tract infection viral serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Retained products of conception serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Right ventricular failure serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Road traffic accident serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Salivary gland neoplasm serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Scrub typhus serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Small intestinal haemorrhage serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Soft tissue infection serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Soft tissue injury serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Spinal column stenosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Spinal cord compression serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Sternal fracture serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Stress fracture serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Stress urinary incontinence serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Subclavian artery stenosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Subcutaneous abscess serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Substance-induced psychotic disorder serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Suicide attempt serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Symphysiolysis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Systemic inflammatory response syndrome serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Thoracic vertebral fracture serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Thrombosis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Tonsillitis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Umbilical hernia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Ureterolithiasis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Urinary tract infection fungal serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Uterine prolapse serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Uterovaginal prolapse serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Uveitis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
VIth nerve paralysis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Vascular occlusion serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Vasculitis cerebral serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Vertigo positional serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Vitreous adhesions serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Renal impairment serious, 10 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Transient ischaemic attack serious, 10 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Acute coronary syndrome serious, 12 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diabetic nephropathy serious, 12 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diabetic foot serious, 15 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hypoglycaemia serious, 17 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Skin ulcer serious, 18 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Adenocarcinoma of colon serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Anaemia iron deficiency serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Angioedema serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Arrhythmia serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Arthritis bacterial serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Asthma serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Back pain serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Basal cell carcinoma serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Blood creatine phosphokinase increased serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Brain oedema serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Carpal tunnel syndrome serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cholangiocarcinoma serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Clostridium difficile colitis serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Confusional state serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cough serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cystitis serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Dementia serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Duodenal ulcer serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Duodenitis serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Encephalopathy serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Fasciitis necrotising serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Fibula fracture serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Gastric ulcer serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Goitre serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Haematoma serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hypertensive heart disease serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Invasive ductal breast carcinoma serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Lung cancer metastatic serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Lung neoplasm serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Maculopathy serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Metastases to bone serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Muscular weakness serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Musculoskeletal chest pain serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Nephrotic syndrome serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Obesity serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Osteomyelitis acute serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Peripheral artery occlusion serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Prostatic adenoma serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pubis fracture serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pyrexia serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Seizure serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Squamous cell carcinoma of skin serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Tension headache serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Thermal burn serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Thyroid mass serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Tibia fracture serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Transitional cell cancer of the renal pelvis and ureter serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Ulna fracture serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Urinary retention serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Vascular graft occlusion serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Ventricular extrasystoles serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Angina pectoris serious, 21 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Urinary tract infection serious, 25 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Abscess limb serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Breast cancer serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cardiac death serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cholecystitis chronic serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Coronary artery occlusion serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diarrhoea serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Gastric cancer serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Gastritis serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Influenza serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Retinal detachment serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Transitional cell carcinoma serious, 3 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Arteriosclerosis coronary artery serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cardio-respiratory arrest serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diverticulitis serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Femoral neck fracture serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hernia inguinal serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Humerus fracture serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Hypotension serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Osteoarthritis spinal serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pancreatitis serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pulmonary fibrosis serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pyelonephritis acute serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Syncope serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Upper gastrointestinal haemorrhage serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Vitreous haemorrhage serious, 4 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Bladder cancer serious, 5 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cholecystitis acute serious, 5 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Cholelithiasis serious, 5 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diabetic gangrene serious, 5 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Disorder peripheral vascular serious, 5 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Femur fracture serious, 5 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Glomerular filtration rate decreased serious, 5 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Colon cancer serious, 6 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Wound infection serious, 6 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Death serious, 7 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diabetic retinopathy serious, 7 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Intestinal obstruction serious, 7 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pulmonary embolism serious, 7 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Non-cardiac chest pain serious, 8 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Prostate cancer serious, 8 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Diabetic ketoacidosis serious, 9 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Extremity necrosis serious, 9 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 2200
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 2200
Sources:
Pneumonia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Type 2 Diabetes Mellitus
Population Size: 13
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no [IC50 18 uM]
no [IC50 39 uM]
no [IC50 65 uM]
no
no
no
no
no
no
no
no
no
no
no (co-administration study)
Comment: no effect when administered with metformin
Page: 70,72
no
no (co-administration study)
Comment: no effect when administered with metformin
Page: 70,72
slight
weak [IC50 19.3 uM]
weak (co-administration study)
Comment: The AUC0-24 and Cmax values of digoxin were approximately 20% and 36% higher, respectively, when digoxin was co-administered with canagliflozin
Page: 70,73
weak [IC50 27 uM]
weak (co-administration study)
Comment: IC50 value obtained when drug is adminstered with testosterone; had not effect on midazolam metabolism (IC50 > 100); Cmax of both oral contraceptive components (ethinyl estradiol and levonorgestrel) was increased (~20%) in presence of canagliflozin; the increase in Cmax for simvastatin and simvastatin acid was 9% and 18%, respectively, while the increase in AUC was 12% and 26%, respectively;
Page: 68,69
weak [IC50 55 uM]
weak [IC50 75 uM]
yes [IC50 16 uM]
yes [IC50 21.5 uM]
yes [Inhibition 100 uM]
yes [Inhibition 100 uM]
yes [Inhibition 100 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (co-administration study)
Comment: efflux was inhibited up to 95% by verapamil (P-gp inhibitor); with cyclosporine increased the AUC of canagliflozin by 23% with no change in Cmax;
Page: 70,72
yes
yes (co-administration study)
Comment: probenecid increased the plasma canagliflozin Cmax and AUCtau by 13% and 21%, respectively; mean plasma Cmax and AUCinf values for canagliflozin were approximately 30% and 52% lower, respectively, when administered with rifampin (inducer)
Page: 68,73,88
yes
yes (pharmacogenomic study)
Comment: probenecid increased the plasma canagliflozin Cmax and AUCtau by 13% and 21%, respectively; mean plasma Cmax and AUCinf values for canagliflozin were approximately 30% and 52% lower, respectively, when administered with rifampin (inducer); carriers of the UGT1A9*3 allele exhibit higher plasma canagliflozin trough concentrations on average
Page: 68,73,88
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
2010 Sep 9
Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
2011 Jan 13
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
2012
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
2013 Jun
Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
2014 Dec 5
Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin.
2014 Sep 25
Patents

Sample Use Guides

The recommended starting dose is 100 mg once daily, taken before the first meal of the day. Dose can be increased to 300 mg once daily in patients tolerating; 100 mg once daily who have an eGFR of 60 mL/min/1.73 m^2 or greater and require additional glycemic control
Route of Administration: Oral
For sodium-dependent glucose uptake in Chinese Hamster Ovary (CHO) cells expressing SGLT1 and SGLT2 co-transporters parental CHO-K (CHOK) cells expressing human or mouse SGLT1 and SGLT2 were seeded into 96-well plates, washed one time with 0.15 ml assay buffer at 37°C. After the assay buffer was removed 0.3–300 nM canagliflozin was added, followed by 10 minutes of incubation.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:39:18 UTC 2021
Edited
by admin
on Fri Jun 25 21:39:18 UTC 2021
Record UNII
6S49DGR869
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CANAGLIFLOZIN ANHYDROUS
Common Name English
CANAGLIFLOZIN [INN]
Common Name English
JNJ-28431754
Code English
D-GLUCITOL, 1,5-ANHYDRO-1-C-(3-((5-(4-FLUOROPHENYL)-2-THIENYL)METHYL)-4-METHYLPHENYL)-
Common Name English
(1S)-1,5-ANHYDRO-1-C-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-D- GLUCITOL
Common Name English
(1S)-1,5-ANHYDRO-1-(3-((5-(4-FLUOROPHENYL)-2-THIENYL)METHYL)-4-METHYLPHENYL)-D-GLUCITOL
Common Name English
CANAGLIFLOZIN [WHO-DD]
Common Name English
TA-7284
Code English
CANAGLIFLOZIN [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000187059
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
WHO-ATC A10BD16
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
NCI_THESAURUS C98083
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
WHO-VATC QA10BX11
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
WHO-ATC A10BX11
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
WHO-ATC A10BK02
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
Code System Code Type Description
EVMPD
SUB33463
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
PRIMARY
PUBCHEM
24812758
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
PRIMARY
NCI_THESAURUS
C91019
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
PRIMARY
NDF-RT
N0000187058
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
PRIMARY Sodium-Glucose Transporter 2 Inhibitors [MoA]
CAS
842133-18-0
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
PRIMARY
FDA UNII
6S49DGR869
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
PRIMARY
DRUG BANK
DB08907
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
PRIMARY
MERCK INDEX
M11716
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
PRIMARY
RXCUI
1546031
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
PRIMARY RxNorm
INN
9225
Created by admin on Fri Jun 25 21:39:18 UTC 2021 , Edited by admin on Fri Jun 25 21:39:18 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
EXCRETED UNCHANGED
URINE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BINDER->LIGAND
Protein binding is independent of canagliflozin plasma concentrations.
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
CYP3A4-mediated (oxidative) metabolism of canagliflozin is minimal (approximately 7%) in humans.
MINOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

Tmax PHARMACOKINETIC SINGLE DOSE

ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC SINGLE DOSE

ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC SINGLE INTRAVENOUS ADMINISTRATION

AT STEADY-STATE

ORAL BIOAVAILABILITY PHARMACOKINETIC